证券代码：603883 证券简称：老百姓 公告编号：2025-033 老百姓大药房连锁股份有限公司关于 2024 年度暨 2025 年 第一季度业绩说明会召开情况的公告（2025 年 6 月纪要） 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 老百姓大药房连锁股份有限公司（以下简称"公司"）于 2025 年 4 月 30 日 在上海证券交易所网站（http://www.sse.com.cn）及指定信息披露媒体披露了 《老百姓大药房连锁股份有限公司 2024 年年度报告》《老百姓大药房连锁股份有 限公司 2025 年一季度报告》。为使广大投资者更加全面、深入地了解公司情况， 公司于 2025 年 6 月 30 日召开了 2024 年度暨 2025 年第一季度业绩说明会，现将 会议召开情况公告如下： 一、业绩说明会召开基本情况 2025 年 6 月 21 日，公司在上海证券交易所网站（http://www.sse.com.cn） 及指定信息披露媒体披露了《关于召开 2024 年度暨 2025 年第一季度业绩说明会 的公告》。 ...

Core Viewpoint - The company aims to enhance its sustainable competitive advantage through comprehensive value chain reforms, despite facing challenges in revenue and profit due to new store openings and goodwill impairment losses [1]. Group 1: Financial Performance - In 2024, the company achieved a revenue of 22.358 billion yuan, a slight decrease of 0.36% year-on-year, while the net profit attributable to shareholders was 519 million yuan, down 44.13% [1]. - The decline in net profit is attributed to the increase in the number of new stores, which are still in the performance growth phase, and the company's recognition of goodwill impairment losses [1]. Group 2: Industry Trends and Strategy - The pharmaceutical retail industry is undergoing significant transformation, shifting from rapid expansion to a phase of differentiation and consolidation [1]. - In the first quarter of 2025, the company reported a net decrease in stores, with 211 new stores opened and 236 closed, resulting in a total reduction of 25 stores [1]. - The company plans to open 1,000 stores in 2025, primarily focusing on franchise stores and converting existing stores to franchises, while also pursuing strategic acquisitions in advantageous markets [1]. Group 3: Compliance and Ecosystem Development - The company emphasizes strengthening its compliance system and self-inspection mechanisms to ensure compliant operations, aiming to enhance store operational quality [2]. - The focus is on developing franchise and alliance businesses to integrate industry resources and build an ecosystem with small and medium-sized pharmacies, aiming to capture opportunities during the industry consolidation phase and increase market share [2]. Group 4: R&D and AI Initiatives - The company has been recognized as a technology center since 2011 and allocates approximately 0.6% of its total revenue annually for R&D, focusing on product and technology development [3]. - The company has developed over 70 self-researched business system products and obtained 102 software copyrights, supporting efficient business operations [3]. - An AI application strategy committee has been established to ensure the implementation of AI initiatives across various business areas, including the development of multiple generative dialogue assistants for different scenarios [3]. Group 5: Future Outlook - The company envisions a transformation from a single "pharmaceutical sales terminal" to a "comprehensive health service complex," aiming to meet evolving consumer health demands [3]. - The strategy includes deepening professional pharmaceutical services, enhancing prescription outsourcing capabilities, and expanding diverse service scenarios through physical pharmacies to create a health community ecosystem [3].

Core Viewpoint - The retail pharmacy industry is experiencing accelerated closures, with a total of 39,228 stores shut down in 2024, leading to a potential recovery in customer traffic and profit margins for leading pharmacies post-industry consolidation [1][2]. Group 1: Industry Trends - The number of closed pharmacies in 2024 is reported as follows: Q1 - 6,778, Q2 - 8,791, Q3 - 9,545, Q4 - 11,414, indicating a significant acceleration in closures, with a net decrease of 3,395 stores in Q4 alone [1]. - The industry is facing a severe environment for small and medium-sized pharmacies due to weak consumer power, medical insurance cost control, and enhanced regulatory measures, leading to a consolidation trend [1]. Group 2: Market Opportunities - Leading retail pharmacies are expected to benefit from a "siphon effect" in customer traffic due to their first-mover advantage in local market outpatient coordination, which may enhance customer spending and overall performance [2]. - The implementation of outpatient coordination policies is anticipated to increase medical insurance spending and related product consumption, potentially raising average transaction values [2]. Group 3: Strategic Initiatives - Leading pharmacies are actively exploring diversified operations and innovative store management to enhance market competitiveness, such as transforming into service complexes and creating new store formats [3]. - Examples include Yifeng Pharmacy's transition towards service complexes and Yixin Hall's development of new store formats to attract more customers [3]. Group 4: Recommended Stocks - Companies that are expected to benefit from the industry cycle and demonstrate superior management capabilities include Yifeng Pharmacy (603939.SH) and Daclin (603233.SH) as recommended stocks, while beneficiaries include Laobaixing (603883.SH), Yixin Hall (002727.SZ), and Jianzhijia (605266.SH) [4].

Meeting Details - The shareholders' meeting was held on June 30, 2025, at the company's conference room in Changsha, Hunan Province [1] - The meeting was attended by shareholders representing 50.8455% of the total shares [1] - Voting was conducted through a combination of on-site and online methods, and the meeting was presided over by Chairman Xie Zilong [1] Voting Results - All non-cumulative voting proposals were approved with high support, including: - Proposal 1: 99.9280% approval from A-shareholders [1] - Proposal 2: 99.9237% approval from A-shareholders [1] - Proposal 3: 99.9208% approval from A-shareholders [1] - Proposal 4: 99.9272% approval from A-shareholders [1] - The voting results indicate a strong consensus among shareholders for the proposed resolutions [2][3] Legal Compliance - The meeting's procedures were confirmed to comply with the Company Law and relevant regulations, ensuring the legality and validity of the meeting and voting results [4]

Core Viewpoint - The legal opinion issued by Hunan Qiyuan Law Firm confirms the legality and validity of the procedures, participants, and voting results of the 2024 Annual General Meeting of the Company held on June 30, 2025 [1][10]. Group 1: Meeting Procedures - The notice for the meeting was announced on the Shanghai Stock Exchange website, detailing the time, location, method, agenda, and registration process [2][3]. - The meeting was held on June 30, 2025, at 15:30 in Changsha, Hunan Province [2]. Group 2: Participant Qualifications - A total of 6 shareholders and their proxies attended the meeting, representing 373,316,894 shares, which is 49.114% of the total shares [3][4]. - The qualifications of the attendees, including current directors, supervisors, and senior management, were verified as compliant with legal and regulatory requirements [4]. Group 3: Voting Procedures and Results - Voting was conducted through both on-site and online platforms, with specific time slots for each [3][5]. - The combined voting results showed overwhelming support for the proposals, with the majority of votes in favor, including 99.9280% for one proposal and 99.7944% for another [5][9]. - The voting results for minority investors also reflected strong support, with over 97% in favor for several proposals [6][8]. Group 4: Conclusion - The law firm concluded that the meeting's procedures, participant qualifications, and voting results were all in compliance with the relevant laws and regulations [10].

证券代码：603883 证券简称：老百姓 公告编号：2025-031 老百姓大药房连锁股份有限公司 关于控股股东股票解押及再质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●老百姓大药房连锁股份有限公司（以下简称"公司"）控股股东老百姓医药集 团有限公司（以下简称"医药集团"）持有公司股份数量为 191,729,175 股，占公司 总股本比例为 25.22%；累计质押股份数量为 118,950,000 股（含本次质押），占其所 持股份比例为 62.04%，占公司总股本比例为 15.65%。控股股东及一致行动人（医药集 团与陈秀兰）合计持有公司股份数量为 205,294,873 股，占公司总股本比例为 27.01%； 累计质押股份数量为 118,950,000 股（含本次质押），占其所持股份比例为 57.94%， 占公司总股本比例为 15.65%。 一、控股股东本次股份质押解除具体情况 公司于 2025 年 6 月 27 日获悉控股股东医药集团在中国证券登记结算有限责任公 司上海分公司办理了将质押给 ...

为出具本法律意见书，本所声明如下： 湖南启元律师事务所 关于老百姓大药房连锁股份有限公司 2024年年度股东大会的 法律意见书 二零二五年六月三十日 致：老百姓大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）接受老百姓大药房连锁股份有限 公司（以下简称"公司"）的委托，指派律师出席了公司 2024 年年度股东大会（以 下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员 及召集人的资格、表决程序和表决结果的合法有效性进行律师见证，并发表本法 律意见。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《老百姓 大药房连锁股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具 本法律意见书。 （一）本所出具本法律意见书是基于公司已承诺所有提供给本所的文件的正 本以及经本所查验与正本保持一致的副本均为真实、完整、可靠，无隐瞒、虚假 或重大遗漏之处。 （二）本所遵循了勤勉尽责和诚实信用原则，严格履行了法定职责，对本法 律意见书 ...

证券代码：603883 证券简称：老百姓 公告编号：2025-032 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 6 月 30 日 (二)股东大会召开的地点：湖南省长沙市开福区青竹湖路 808 号老百姓 15 楼会 议室 老百姓大药房连锁股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 342 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 386,474,468 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 50.8455 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票和网络投票相结合的方式召开，老百姓大药房连锁股份有 限公司（以下简称"公司"）董事会召集本次会议，本次 ...

Core Viewpoint - The explosive growth of household savings in China since 2022 is attributed to multiple underlying factors rather than simply a reluctance to consume [1][8]. Group 1: Savings Growth - By September 2022, the total household savings reached an unprecedented 115.7 trillion yuan, with an increase of 13.21 trillion yuan in the first three quarters of 2022 compared to only 8.49 trillion yuan in the same period of 2021, marking a year-on-year increase of 4.72 trillion yuan [1]. - Despite a general decline in consumption, the savings continue to rise, indicating that the situation is influenced by more than just consumer sentiment [3][8]. Group 2: Factors Influencing Savings - The repeated COVID-19 outbreaks and extensive lockdown measures have severely restricted residents' mobility and consumption, leading to a significant decline in offline spending [5]. - Increased risk awareness due to the pandemic has prompted residents to prioritize savings for potential future uncertainties, such as unemployment or health issues, viewing savings as a "lifeline" [5][6]. - The cooling real estate market has shifted investment behaviors, with many individuals postponing or abandoning home purchases, leading to increased deposits as funds originally earmarked for down payments are saved instead [5][6]. Group 3: Investment Channels - The lack of safe and reliable investment options has contributed to the rise in savings, as high-risk stock market investments and declining returns from mutual funds have discouraged residents from investing [6]. - With bank deposit interest rates remaining low, saving in banks has become a relatively safer option compared to the risks associated with other investment avenues [6][8]. Group 4: Policy Recommendations - Simply lowering deposit interest rates may not effectively stimulate consumption; a more comprehensive set of policy measures is needed to enhance consumer confidence and promote economic recovery [3][8].

Core Viewpoint - The price of Moutai, once considered a luxury item, has significantly decreased, allowing consumers to purchase it at its original price of 1499 yuan, marking a shift in the market dynamics of the liquor industry [1][5][10]. Price Trends - In 2021, Moutai's market price soared to over 3000 yuan, with consumers often needing to rely on luck or connections to purchase it at retail price [3][5]. - Since late last year, Moutai's price has been on a downward trend, dropping from over 2800 yuan to 1499 yuan, with increased availability on e-commerce platforms [5][8]. Market Dynamics - The decline in Moutai's price is attributed to several factors, including reduced consumer spending on luxury items due to economic conditions, increased supply from the manufacturer, and a decrease in demand from public spending [5][6]. - Moutai's previous high prices were driven by its status as a social currency in China, but this bubble has burst as economic realities set in [6][9]. Industry Implications - Moutai's price reduction is expected to impact the entire liquor industry, as other high-end brands like Wuliangye and Guojiao may also need to lower their prices to remain competitive [8][9]. - The shift in pricing strategy may force liquor companies to focus more on quality, service, and value rather than relying on price increases for profitability [9][10]. Consumer Behavior - The price drop may change younger consumers' perceptions of liquor, making it more accessible and potentially increasing its consumption among this demographic [9][11]. - The return to a more reasonable price point for Moutai and other liquors could signal a broader market correction, moving away from speculative pricing [10][11].